Dermatology - HCP
XOLAIR® (omalizumab) logo
Dermatology
XOLAIR® (omalizumab)

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.


Source URL: https://www.pro.novartis.com/uk-en/medicines/dermatology